Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Reddit Inc (RDDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Reddit Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $355.41 (market cap $9.43B), while Reddit Inc trades at $152.81 (market cap $30.05B). The key difference: Reddit Inc is far larger — about 3.2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Reddit Inc nearer its low. Which is the better fit depends on your goals.
| BIO | RDDT | |
|---|---|---|
Market Cap | $9.43B | $30.05B |
Sector | Health | Media |
52-Week High | $356.25 | $270.71 |
52-Week Low | $241.71 | $121.84 |
Enterprise Value | $9.18B | $27.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Reddit (RDDT) trades at $152.50, down 3.91% amid a bearish technical signal despite strong Q2 2026 results showing 61% revenue growth and earnings beats. The stock faces selling pressure despite analyst consensus of $220.25 price target and 64% buy ratings. Recent CEO share sales and search traffic concerns have weighed on sentiment, though fundamentals remain robust with 31.35% net margins and positive cash flow trends.
The outlook remains bifurcated with strong fundamental performance contrasting with technical weakness. Investment opportunity lies in discounted valuation post-selloff and AI monetization potential, while risks include user growth sustainability and competitive pressures in social media landscape. The stock presents a growth-at-reasonable-price case if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Reddit Inc
Reddit Inc. operates a vast network of online communities organized around various interests, known as 'subreddits'. Functioning as a hybrid of a social media platform and a discussion forum, the company generates revenue primarily through advertising and premium subscriptions. Reddit is a major hub for user-generated content, trending news, and viral discussions, and it is a key player in the digital advertising and social media landscape.
Read more on RDDT →
